Year 2019 / Volume 111 / Number 2
Original
Hepatitis B virus in patients with chronic hepatitis C treated with direct antiviral agents

129-133

DOI: 10.17235/reed.2018.5667/2018

María Luisa Gutiérrez García, María Luisa Manzano Alonso, Juan Ángel Ferrer Rosique, Raquel Muñoz Gómez, Sonia Alonso López, Inmaculada Fernández Álvarez, Conrado M. Fernández Rodríguez,

Abstract
Introduction: cases of hepatitis B virus (HBV) reactivation have been reported in patients with hepatitis C virus (HCV) treated with direct antiviral agents (DAA). Objectives and methods: the main objectives of the present study are: a) to determine the prevalence of HBV/HCV coinfection in HCV patients treated with DAAs in the Autonomous Community of Madrid (CM) and also to determine the incidence and clinical relevance of HBV reactivation; and b) to determine the HBV screening rates in HCV patients in our region. For that purpose, 1,337 HCV patients were consecutively treated with DAAs in two hospitals located in South CM between January 2015 and June 2017. Results: nine of the 1,337 (0.67%) participants were HBsAg positive and 356 (26.6%) had previous HBV infection markers. Two of the four (50%) HBsAg positive patients with untreated HBV developed a virological reactivation, but not a biochemical reaction. Of the 356 patients with previous HBV infection markers, all had normal transaminases at the end of treatment and during follow-up. The HBV screening rate amounted to 92.9% of the cohort. Conclusions: the prevalence of HBV (HBsAg positive) infection in patients with chronic hepatitis C in the southern area of the CM is low. HBV reactivation in HBsAg positive patients treated with DAAs is common, although without clinical relevance. In our region, there is a high rate of HBV screening in patients with HCV that are likely treated with DAAs.
Share Button
New comment
Comments
No comments for this article
References
1. Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viral interactions and management. Gastroenterology 2015;28:221-8.
2. Bini EJ, Perumalsswami PV. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions. Hepatology 2010;51:759-66.
3. Fukuda R, Ishimura N, Niigaki M, et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 1999;58:201-7.
4. Liu JY, Sheng YJ, HU HD, et al. The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis. Virol J 2012;9:186. doi: 10.1186/1743-422X-9-186.
5. Takayama H, Sato T, Ikeda F, et al. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res 2016;46:489-91.
6. Ende AR, Kim NH, Yeh MM, et al. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep 2015;9:164.
7. Collins JM, Raphael KL, Terry C, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis 2015;61:1302-6.
8. De Monte A, Courjon J, Anty R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge. J ClinVirol 2016;78:27-30.
9. EMA’s Pharmacovigilance Risk Assessment Committee. PRAC warns of risk
of hepatitis B re-activation with direct- acting antivirals for hepatitis C. 2016 [Dec 5,
2016]. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document
/Directacting_antivirals_for_hepatitis_C_20/Recommendation_provided_by_Pharmacovi gilance_Risk_Assessment_Committee/WC500217495.pdf.
10. U.S.Food and Drug Administration. FDA Drug Safety Communication: FDA
warns about the risk of hepatitis B reactivating in some patients treated with direct acting antivirals for hepatitis C. 2016 [Dec 5, 2016].
http://www.fda.gov/downloads/Drugs/DrugSafety/UCM523499.pdf.
11. Londoño MC, Sens S, Mariño Z, et al. Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen. Aliment Pharmacol Ther 2017;45:1156-61.
12. Wang C, Ji D, Chen J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct/acting antiviral agents. Clin Gastroenterol Hepatol 2017;15:132-6.
13. Belperio P, Shahoumian T, Mole L, et al. Evaluation of Hepatitis B reactivation among 62920 veterans treated with oral hepatitis C antivirals. Hepatology 2017, 66:27-36.
14. Chen G, Wang C, Chen J, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis. Hepatology 2017; 66: 13-26.
15. Serti E, Chepa-Lotrea X, Kim YJ, et al. Gastroenterology 2015;149:190-200.
16. Mondelli MU. Gastroenterology 2015;149:25-8.
Citation tools
Gutiérrez García M, Manzano Alonso M, Ferrer Rosique J, Muñoz Gómez R, Alonso López S, Fernández Álvarez I, et all. Hepatitis B virus in patients with chronic hepatitis C treated with direct antiviral agents . 5667/2018


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 2192 visits.
This article has been downloaded 257 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 20/04/2018

Accepted: 21/07/2018

Online First: 13/11/2018

Published: 01/02/2019

Article revision time: 68 days

Article Online First time: 207 days

Article editing time: 287 days


Share
This article has been rated by 2 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2024 y Creative Commons. The Spanish Journal of Gastroenterology